Skip to main content
An official website of the United States government
Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Therapeutic and Preventative Cancer Vaccines: The Last 30 Years

  • Date: Wednesday, June 7, 2023
  • Time: 3:00pm EDT to 4:00pm EDT

The NCI Division of Cancer Prevention Immunology Interest Group (DCP IIG) is pleased to announce the launch of a new seminar series focused on cancer prevention, interception, and immuno-oncology. Please join us for the upcoming inaugural seminar.

Speaker

Olja Finn, Ph.D.

The inaugural speaker is Dr. Olivera (Olja) Finn, University of Pittsburgh Distinguished Professor of Immunology and Surgery and Founding Chair of the Department of Immunology, the position she held from 2001 to 2013. After receiving her Ph.D. in Medical Microbiology at Stanford University in 1980 and completing her postdoctoral training in Immuno-oncology there in 1982, Dr. Finn started her research at Duke University and in 1991 moved to the University of Pittsburgh. She gained prominence through her basic and applied research on tumor antigens and cancer vaccines. She has served and currently serves on NCI study sections and was a member of the NCI Board of Scientific Counselors. Dr. Finn is a member of the American Association of Immunologists where she served as President in 2007/2008. She served two terms as Councilor of the International Union of Immunology Societies (IUIS) and was Chair of the IUIS Committee on Gender Equality and Career Development. She is a member of the American Association for Cancer Research (AACR) and the Society for Immunotherapy of Cancer (SITC). Dr. Finn received numerous awards, including the AAI Lifetime Achievement Award (2016), the NCI Outstanding Investigator Award (2016), the AACR CIR Lloyd Old Cancer Immunology Prize (2017), and SITC Richard Smalley Award (2019). In 2019 she was inducted into the inaugural class of AAI Distinguished Fellows and in 2022 became a Fellow of the SITC Immuno-Oncology Academy.

Host

Shizuko Sei, M.D.
Co-Chief, Chemopreventive Agent Development

Contact Person

Wosene Asefa
wosene.asefa@nih.gov